Free Trial
NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Stock Price, News & Analysis

$50.88
+0.89 (+1.78%)
(As of 07/12/2024 ET)
Today's Range
$48.47
$51.25
50-Day Range
$36.55
$53.15
52-Week Range
$12.75
$67.21
Volume
327,260 shs
Average Volume
542,314 shs
Market Capitalization
$870.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$137.38

Praxis Precision Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
170.0% Upside
$137.38 Price Target
Short Interest
Bearish
9.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of Praxis Precision Medicines in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($10.13) to ($9.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

436th out of 917 stocks

Pharmaceutical Preparations Industry

206th out of 435 stocks

PRAX stock logo

About Praxis Precision Medicines Stock (NASDAQ:PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX Stock Price History

PRAX Stock News Headlines

Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 5.2%
There’s something very “off” about this situation
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
There’s something very “off” about this situation
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
See More Headlines
Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/13/2024
Today
7/13/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAX
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$137.38
High Stock Price Target
$270.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+170.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-123,280,000.00
Net Margins
-5,711.85%
Pretax Margin
-5,711.85%

Debt

Sales & Book Value

Annual Sales
$2.45 million
Book Value
$7.92 per share

Miscellaneous

Free Float
16,646,000
Market Cap
$870.56 million
Optionable
Optionable
Beta
2.74
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Marcio Silva De'Souza M.B.A. (Age 45)
    President, CEO & Director
    Comp: $1.18M
  • Mr. Timothy Edwin Kelly (Age 50)
    CFO & Treasurer
    Comp: $691.58k
  • Mr. Alex Nemiroff J.D. (Age 44)
    General Counsel & Secretary
    Comp: $577.34k
  • Dr. Steven Petrou B.Sc. (Hons.)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Lauren Mastrocola
    VP of Finance & Principal Accounting Officer
  • Dr. Karl Hansen Ph.D.
    Chief Technical Operations Officer
  • Alex Kane
    VP of Investor Relations & Corporate Communications
  • Ms. Kelly McCue
    Chief People Officer
  • Ms. Alyssa J. S. Wyant (Age 49)
    Chief Regulatory & Quality Officer
  • Ms. Megan T. Sniecinski (Age 42)
    Chief Business Officer

PRAX Stock Analysis - Frequently Asked Questions

How have PRAX shares performed this year?

Praxis Precision Medicines' stock was trading at $22.28 at the start of the year. Since then, PRAX shares have increased by 128.4% and is now trading at $50.88.
View the best growth stocks for 2024 here
.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced its quarterly earnings results on Monday, May, 13th. The company reported ($2.84) earnings per share for the quarter, missing the consensus estimate of ($2.01) by $0.83. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $2.75 million. Praxis Precision Medicines had a negative net margin of 5,711.85% and a negative trailing twelve-month return on equity of 101.99%.

When did Praxis Precision Medicines' stock split?

Praxis Precision Medicines shares reverse split before market open on Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Praxis Precision Medicines IPO?

Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRAX) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners